
HENRY SCHEIN INC
HSICNASDAQTrading Snapshot
- Day Range
- $88.07 β $90.13
- 52-Week Range
- $61.95 β $92.18
- Volume
- $2.58B
- Avg Volume
- $2.26B
- Shares Outstanding
- 113.9M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $13.18B
- Last Q Revenue
- $3.46B
- P/E Ratio
- 24.3
- P/S Ratio
- 0.7x
- EPS (TTM)
- $3.43
- Dividend Yield
- β
Why Investors Own HSIC
- βHigh-growth profile β revenue up +15.5% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 23% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HENRY SCHEIN INC
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Should Value Investors Buy Henry Schein (HSIC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HSIC or SAUHY: Which Is the Better Value Stock Right Now?
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
Barclays Maintains Overweight on Henry Schein, Raises Price Target to $100
Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises the price target from $86 to $100.

Should Henry Scheinβs Raised 2026 Sales Growth Guidance Require Action From Henry Schein (HSIC) Investors?
Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net income to US$94 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Importantly for long-term watchers, management also raised its 2026 total sales growth guidance, signaling greater confidence in the companyβs operating initiatives and demand trends. Now weβll examine how Henry Scheinβs raised 2026 sales outlook reshapes its existing...
UBS Maintains Neutral on Henry Schein, Raises Price Target to $94
UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the price target from $89 to $94.
Citigroup Maintains Buy on Henry Schein, Raises Price Target to $112
Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price target from $100 to $112.